P
Peter Hau
Researcher at University Hospital Regensburg
Publications - 230
Citations - 21991
Peter Hau is an academic researcher from University Hospital Regensburg. The author has contributed to research in topics: Temozolomide & Glioma. The author has an hindex of 44, co-authored 196 publications receiving 18778 citations. Previous affiliations of Peter Hau include University of Regensburg.
Papers
More filters
Journal ArticleDOI
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp,Monika E. Hegi,Warren P. Mason,Martin J. van den Bent,Martin J.B. Taphoorn,Robert C. Janzer,Samuel K. Ludwin,Anouk Allgeier,Barbara Fisher,Karl Belanger,Peter Hau,Alba A. Brandes,J.M.M. Gijtenbeek,Christine Marosi,Charles J. Vecht,Karima Mokhtari,Pieter Wesseling,Salvador Villà,Elizabeth Eisenhauer,Thierry Gorlia,Michael Weller,Denis Lacombe,J. Gregory Cairncross,René-Olivier Mirimanoff +23 more
TL;DR: Benefits of adjuvant temozolomide with radiotherapy lasted throughout 5 years of follow-up, and a benefit of combined therapy was recorded in all clinical prognostic subgroups, including patients aged 60-70 years.
Journal ArticleDOI
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Monika E. Hegi,Annie-Claire Diserens,Thierry Gorlia,Marie-France Hamou,Nicolas de Tribolet,Nicolas de Tribolet,Michael Weller,Johan M. Kros,Johannes A. Hainfellner,Warren P. Mason,Luigi Mariani,Jacoline E C Bromberg,Peter Hau,René O. Mirimanoff,J. Gregory Cairncross,Robert C. Janzer,Roger Stupp +16 more
TL;DR: Patients with glioblastoma containing a methylated MGMT promoter benefited from temozolomide, whereas those who did not have a methylation of theMGMT promoter did notHave such a benefit and were assigned to only radiotherapy.
Journal ArticleDOI
CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles.
Dagmar Beier,Peter Hau,Martin Proescholdt,Annette Lohmeier,Jörg Wischhusen,Peter J. Oefner,Ludwig Aigner,Alexander Brawanski,Ulrich Bogdahn,Christoph P. Beier +9 more
TL;DR: Together, the data provide first evidence that CD133(+) CSC maintain only a subset of primary glioblastomas, with apparent stem cell-like properties but distinct molecular profiles and growth characteristics in vitro and in vivo.
Journal ArticleDOI
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial
Roger Stupp,Roger Stupp,Monika E. Hegi,Thierry Gorlia,Sara Erridge,James Perry,Yong-Kil Hong,Kenneth Aldape,Benoit Lhermitte,Torsten Pietsch,Danica Grujicic,Joachim P. Steinbach,Wolfgang Wick,Rafal Tarnawski,Do-Hyun Nam,Peter Hau,Astrid Weyerbrock,Martin J B Taphoorn,Chiung-Chyi Shen,Nalini Rao,László Thurzó,Ulrich Herrlinger,Tejpal Gupta,Rolf-Dieter Kortmann,Krystyna Adamska,Catherine McBain,Alba A. Brandes,Joerg C. Tonn,Oliver Schnell,Thomas Wiegel,Chae-Yong Kim,Louis B. Nabors,David A. Reardon,Martin J. van den Bent,Christine Hicking,Andriy Markivskyy,Martin Picard,Michael Weller +37 more
TL;DR: This multicentre, open-label, phase 3 study investigated the efficacy of cilengitide in patients from 146 study sites in 25 countries and found none of the predefined clinical subgroups showed a benefit.
Journal ArticleDOI
Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study
Ulrich Bogdahn,Peter Hau,G. Stockhammer,N. K. Venkataramana,Ashok Kumar Mahapatra,Ashish Suri,A. Balasubramaniam,Sreejayan Nair,V. Oliushine,V. E. Parfenov,I. E. Poverennova,M. Zaaroor,P. Jachimczak,Stephan Ludwig,S. Schmaus,H. Heinrichs,Karl-Hermann Schlingensiepen +16 more
TL;DR: In this article, the authors evaluated the efficacy and safety of trabedersen (AP 12009) administered intratumorally by convection-enhanced delivery compared with standard chemotherapy in patients with recurrent/refractory high-grade glioma.